Pharma & Biotech
-
Merck’s Montco Tax Challenge Sparks Concern Over School Funding
Merck’s massive presence in Upper Gwynedd has long made the pharmaceutical giant one of Montgomery County’s most influential employers and taxpayers. Now, a new tax assessment appeal tied to the company’s local campuses could have major financial implications for the community, writes Dan Sokil for The Repoter. Merck is seeking new assessments for two large…
-
Malvern Gene Company to Raise $115M from Convertible Notes While Dealing with Stock Decline
Malvern-based Ocugen saw its stock fall almost 20 percent after an announcement to use convertible notes to pay down existing debt and fund ongoing drug development, writes John George for the Philadelphia Business Journal. The gene therapy company plans to raise $115 million through these notes, which is debt that be turned into stock. The…
-
ESPN: Strokes of Genius: Abington Olympic Gold-Medalist Rower and Her mRNA- Expert Mom Race to the Top of Their Careers
For Susan Francia, a two-time Olympic gold medalist in rowing and daughter of newly-famous Abington scientist Dr. Katalin Kariko, hard work was always a part of life, she wrote for ESPN. She was taught by her mother that if she embraced hard work, it would bring her rewards in life. This philosophy turned true for…
-
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal
Madrigal Pharmaceuticals is making another major move in the rapidly growing liver disease treatment market, writes John George for The Philadelphia Business Journal. The West Conshohocken company has a potential $1 billion licensing agreement aimed at expanding its pipeline of therapies for MASH. Madrigal announced it will pay California-based Arrowhead Pharmaceuticals $25 million upfront for…
-
Conshohocken’s Cencora Prepares for Leadership Change This Summer
Conshohocken’s Cencora is preparing for a major leadership transition as executive vice president and chief financial officer James Cleary plans to step down, writes Sydney Halleman for HealthCareDive. The company said Cleary will officially step down on June 30, but will remain with Cencora through the end of the year in an advisory capacity as…
-
Montco Vaccine Maker Bets Its Data May Be Worth as Much as Its Science
Ambler’s MBF Therapeutics believes the data behind its vaccines could become just as valuable as the vaccines themselves, writes Holly Quinn for Technical.ly. The company has spent more than a decade developing a non-viral vaccine platform for animal health. According to CEO and cofounder Tom Tillett, MBF is exploring whether its detailed immune-response data could…
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in 2025, writes John George for the Philadelphia Business Journal. The treatment for MASH, a progressive liver disease metabolic dysfunction-associated steatohepatitis, marked the company’s largest advancement since being founded in 2011.…
-
Conshohocken’s Cencora Strikes $3.5B Animal Health Deal
Conshohocken’s Cencora is reshaping its business with a $3.5 billion deal involving its animal health division, writes John George for The Philadelphia Business Journal. The wholesale drug distributor announced it will combine MWI Animal Health with Maine-based Covetrus, creating a newly merged company focused exclusively on animal health technology and distribution. In return, Cencora will…
-
Johnson & Johnson Expands its Montco Footprint with $1B Investment
Johnson & Johnson is making another major bet on Montgomery County, writes Harold Brubaker for The Philadelphia Inquirer. The pharmaceutical giant announced plans to invest more than $1 billion to build a new cell therapy manufacturing facility in Lower Gwynedd Township near its Spring House campus. The plant is expected to create about 500 jobs…
-
Conshohocken’s Madrigal Makes $4B Bet on the Future of Liver Disease Treatment
Conshohocken’s Madrigal Pharmaceuticals is making a major move that could reshape the future of liver disease treatment, writes John George for The Philadelphia Business Journal. The biotech firm announced a global licensing agreement potentially worth more than $4 billion. The deal will expand its pipeline of therapies targeting metabolic dysfunction-associated steatohepatitis, or MASH. Under the…
-
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor
Doylestown-based Aprea Therapeutics has named Eugene Kennedy, MD, as chief medical advisor, adding a seasoned leader in oncology drug development to its executive team. Aprea is a clinical-stage biopharmaceutical company advancing innovative therapies targeting cancer-specific vulnerabilities while minimizing damage to healthy cells. Kennedy joins after early clinical proof-of-concept was demonstrated for the WEE1 inhibitor APR-1051…
-
Lower Gwynedd Biotech Third Arc Bio Lands $52M to Expand Drug Pipeline
A fast-growing biotechnology company based in Lower Gwynedd has secured major new funding to accelerate the development of next-generation medicines, writes John George for The Philadelphia Business Journal. Third Arc Bio announced it has closed a $52 million Series A extension that will help expand its pipeline of drug candidates targeting cancer, immunology, and inflammatory…
-
Eli Lilly to Build $3.5B Weight-Loss Drug Plant in Upper Macungie
Eli Lilly plans to build a $3.5 billion pharmaceutical plant in Upper Macungie Township, just north of Montgomery County, for its next-generation weight-loss medicines, writes Harold Brubaker for The Philadelphia Inquirer. The selection of the Lehigh Valley for one of Eli Lilly’s four new U.S. factories represents a significant win for Pennsylvania as it competes…
-
Conshohocken-Based Health Tech Startup Keriton Acquired by Natus Sensory
Keriton, a Conshohocken-based health-tech startup, has been acquired by Natus Sensory, a global provider of pediatric and neonatal medical technology, for an undisclosed sum, writes Holly Quinn for Technical.ly. Focused on improving feeding safety in NICUs (neonatal intensive care units), Keriton’s feeding-management platform should gain wider adoption worldwide as a result of the deal. “They’ve…
-
Conshohocken-based Cencora’s New Partnership Speeds Rare Disease Treatment to Market
Conshohocken’s Cencora partnered with Curant Rare to help rare disease treatments reach patients faster and more smoothly, the companies announced in a press release. Curant Rare announced a strategic collaboration with Cencora to support pharmaceutical companies bringing rare disease therapies to market. Rare disease drugs often face added hurdles, including complex regulations and limited patient…
-
Plymouth Meeting Pharmaceutical Company Eyes $1B Milestone
Harmony Biosciences says its flagship narcolepsy drug is on track to hit a major milestone, writes John George for The Philadelphia Business Journal. The Plymouth Meeting business expects Wakix to surpass $1 billion in annual revenue this year. The drug treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. It generated $868 million in…
-
Merck Leads the Pharmaceutical Pack with Net-Zero Strategy
Pharmaceutical giant Merck is accelerating its push toward net-zero emissions, renewable energy and long-term environmental stewardship, writes Chloe Williment for Sustainability Magazine. Merck has committed to reducing energy demand while rapidly expanding its use of renewable power, particularly across energy-intensive healthcare manufacturing. Over the past five years, the company has secured 209 megawatts of renewable…
-
Yardley-Based Jubilant Therapeutics Appoints Industry Veteran as New CEO
Jubilant Therapeutics, a Yardley-based biopharmaceutical company focused on cancer and autoimmune disease treatments, has named Daniel J. O’Connor to be its new CEO, writes John George for the Philadelphia Business Journal. O’Connor brings with him more than thirty years of executive experience in the life sciences industry. He previously led Ambryx Biopharma, a San Diego…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
